OpenResearchAlpha

Small · 16 Nov 2026

Multimodal Nanohybrid Artificial Antibodies as PD‐L1 Immune Checkpoint Antagonists for Potentiated Combination Cancer Immunotherapy

Sin Lee, Yujin Choi, Yoonhee So, Yejoo Yu, Chanhee Choi, Hongwon Kim, Sohyun Moon, Seongyeon Choi, Hwankyu Lee, Jong‐Ho Kimh-index 19

0
Citations
no database records one yet
0
Citations in 2026
so far
19
Leading author's h-index
Jong‐Ho Kim, in QAI's scholar index
38
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

ABSTRACT Monoclonal antibody–based PD‐1/PD‐L1 blockade immunotherapy is an innovative approach to cancer treatment. However, its clinical efficacy remains limited, with low response rates in patients, requiring multimodal therapeutic approaches. This study reports the development of synthetic nanohybrid artificial antibodies (SNA) with both PD‐L1 blockade and photothermal effects as multimodal immune checkpoint antagonists for effective combination cancer immunotherapy. Multimodal SNAs are prepared by assembling multivalent tripeptide recognition phases onto rigid scaffolds of WS 2 or MoSe 2 nanosheets with photothermal effect. The SNAs, comprising an FNP tripeptide assembly on nanosheets (MoSe 2 ‐FNP & WS 2 ‐FNP), selectively bind to PD‐L1 with sub‐nanomolar apparent affinity (0.785 nM), thereby effectively blocking its interaction with PD‐1 on T cells. Thorough experimental and computational results reveal that the recognition selectivity of the SNAs for PD‐L1 is attributed to their multivalent hydrogen bonds and hydrophobic interactions with the PD‐L1 epitope. The multimodal MoSe 2 ‐FNP more effectively eradicates tumor cells by combining a PD‐L1 blockade with photothermal effect. The multimodal MoSe 2 ‐FNP‐based combination immunotherapy accelerates the infiltration of antitumoral immune cells into solid tumors in mice, and its therapeutic efficacy is significantly enhanced compared with monoclonal antibody treatment. This SNA‐based cancer immunotherapy thus holds considerable promise as an effective therapeutic avenue for cancer treatment.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Jong‐Ho Kim has the highest h-index among the authors (19).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (10)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (38)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 18 more references

A free account opens the rest of the citing papers and references on every paper’s page.

Multimodal Nanohybrid Artificial Antibodies as PD‐L1 Immune Checkpoint Antagonists for Potentiated Combination Cancer Immunotherapy - QAI OpenResearch